These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37237491)

  • 1. Role of Cytokines and Growth Factors in the Manufacturing of iPSC-Derived Allogeneic Cell Therapy Products.
    Kao CY; Mills JA; Burke CJ; Morse B; Marques BF
    Biology (Basel); 2023 May; 12(5):. PubMed ID: 37237491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.
    Zhou Y; Li M; Zhou K; Brown J; Tsao T; Cen X; Husman T; Bajpai A; Dunn ZS; Yang L
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of an induced pluripotent stem cell-specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products.
    Chung L; Cogburn LA; Sui L; Dashnau JL
    Cytotherapy; 2022 Jul; 24(7):733-741. PubMed ID: 35461759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell-derived allogeneic cell therapies.
    Dashnau JL; Xue Q; Nelson M; Law E; Cao L; Hei D
    Cytotherapy; 2023 Jan; 25(1):1-13. PubMed ID: 36109321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous Induced Pluripotent Stem Cell-Based Cell Therapies: Promise, Progress, and Challenges.
    Madrid M; Sumen C; Aivio S; Saklayen N
    Curr Protoc; 2021 Mar; 1(3):e88. PubMed ID: 33725407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing Manufacturing Challenges for Commercialization of iPSC-Based Therapies.
    Dashtban M; Panchalingam KM; Shafa M; Ahmadian Baghbaderani B
    Methods Mol Biol; 2021; 2286():179-198. PubMed ID: 32430594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.
    Bogomiakova ME; Sekretova EK; Anufrieva KS; Khabarova PO; Kazakova AN; Bobrovsky PA; Grigoryeva TV; Eremeev AV; Lebedeva OS; Bogomazova AN; Lagarkova MA
    Stem Cell Res Ther; 2023 Apr; 14(1):77. PubMed ID: 37038186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Immunosuppressive Cell Therapy to Prolong Survival of Induced Pluripotent Stem Cell-Derived Allografts.
    Sasaki H; Wada H; Baghdadi M; Tsuji H; Otsuka R; Morita K; Shinohara N; Seino K
    Transplantation; 2015 Nov; 99(11):2301-10. PubMed ID: 26360665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fit-For-All iPSC-Derived Cell Therapies and Their Evaluation in Humanized Mice With NK Cell Immunity.
    Flahou C; Morishima T; Takizawa H; Sugimoto N
    Front Immunol; 2021; 12():662360. PubMed ID: 33897711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of mesenchymal stem cells from human induced pluripotent stem cells on differentiation, maturation, and function of dendritic cells.
    Gao WX; Sun YQ; Shi J; Li CL; Fang SB; Wang D; Deng XQ; Wen W; Fu QL
    Stem Cell Res Ther; 2017 Mar; 8(1):48. PubMed ID: 28253916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
    Nianias A; Themeli M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syngeneic Mesenchymal Stem Cells Reduce Immune Rejection After Induced Pluripotent Stem Cell-Derived Allogeneic Cardiomyocyte Transplantation.
    Yoshida S; Miyagawa S; Toyofuku T; Fukushima S; Kawamura T; Kawamura A; Kashiyama N; Nakamura Y; Toda K; Sawa Y
    Sci Rep; 2020 Mar; 10(1):4593. PubMed ID: 32165680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.
    Lupo KB; Moon JI; Chambers AM; Matosevic S
    Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of universal natural killer cells from a cryopreserved cord blood mononuclear cell-derived induced pluripotent stem cell library.
    Du W; Cui L; Zhang J; Zhang H; Liu R; Yang W; Zhang Y
    FEBS Open Bio; 2022 Oct; 12(10):1771-1781. PubMed ID: 35747945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers.
    Shafa M; Yang F; Fellner T; Rao MS; Baghbaderani BA
    Front Med (Lausanne); 2018; 5():69. PubMed ID: 29600249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.
    Cichocki F; Bjordahl R; Gaidarova S; Mahmood S; Abujarour R; Wang H; Tuininga K; Felices M; Davis ZB; Bendzick L; Clarke R; Stokely L; Rogers P; Ge M; Robinson M; Rezner B; Robbins DL; Lee TT; Kaufman DS; Blazar BR; Valamehr B; Miller JS
    Sci Transl Med; 2020 Nov; 12(568):. PubMed ID: 33148626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Monkey Induced Pluripotent Stem Cell-Derived Cartilage Lacking Major Histocompatibility Complex Class I Molecules on the Cell Surface.
    Okutani Y; Abe K; Yamashita A; Morioka M; Matsuda S; Tsumaki N
    Tissue Eng Part A; 2022 Jan; 28(1-2):94-106. PubMed ID: 34182799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells.
    Shafa M; Walsh T; Panchalingam KM; Richardson T; Menendez L; Tian X; Suresh Babu S; Dadgar S; Beller J; Yang F; Baghbaderani BA
    Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.